Scribe Therapeutics, Inc. (SCTX) IPO - S-1 Filing, Stock & Insider Activity
Scribe Therapeutics, Inc. IPO - Status & S-1 Filing
- Ticker: SCTX
- Status: Priced - IPO complete
- S-1 filed: 2026-07-02
- Effective: 2026-07-23
- IPO / pricing date: 2026-07-27
- Exchange: NASDAQ
- Expected price range: $13.00–$15.00
- Shares offered: 8,580,000
- SEC CIK: 0001853921 · View the S-1 on SEC EDGAR →
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
Scribe Therapeutics, Inc. (SCTX) has filed 13 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-29. Insiders disclosed 9 open-market purchases totaling $71.34M. 1 Form 8-K material event filing was reported by SCTX in the last 90 days. InsiderAlpha tracks every SCTX SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Scribe Therapeutics, Inc. (SCTX)
Scribe Therapeutics, Inc. trades under the ticker SCTX. InsiderAlpha tracks 13 primary SEC Form 4 filings from 11 reporting insiders for SCTX since 2026, sourced directly from SEC EDGAR.
| SEC CIK | 0001853921 |
|---|
90-Day SEC Filing Activity
| Insider purchases (90d) | 9 ($71.34M) |
|---|---|
| Form 4 filings (90d) | 13 |
| Form 8-K filings (90d) | 1 |
| Latest Form 4 filing | 2026-07-29 |
Recent SCTX Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Behzad Aghazadeh | Director | P - Open-market purchase | 7.9K | $18.25 | $144K | SEC | |
| Carl L. Gordon | Director | P - Open-market purchase | 1.00M | $15.00 | $15.00M | SEC | |
| ORBIMED ADVISORS LLC | Director | J - Other acquisition / disposition | 348.8K | - | - | SEC | |
| ORBIMED ADVISORS LLC | Director | P - Open-market purchase | 1.00M | $15.00 | $15.00M | SEC | |
| AH Bio Fund II, L.P. | 10% Owner | J - Other acquisition / disposition | 2.05M | - | - | SEC | |
| AH Bio Fund II, L.P. | 10% Owner | J - Other acquisition / disposition | 697.6K | - | - | SEC | |
| AH Bio Fund II, L.P. | 10% Owner | P - Open-market purchase | 333.3K | $15.00 | $5.00M | SEC | |
| Carl L. Gordon | Director | J - Other acquisition / disposition | 348.8K | - | - | SEC | |
| Jennifer A. Doudna | 10% Owner | J - Other acquisition / disposition | 12.5K | - | - | SEC | |
| Behzad Aghazadeh | Director | P - Open-market purchase | 2.33M | $15.00 | $35.00M | SEC | |
| Behzad Aghazadeh | Director | P - Open-market purchase | 50.0K | $22.31 | $1.12M | SEC | |
| Svetlana Lucas | Chief Business Officer | P - Open-market purchase | 3.0K | $15.00 | $45K | SEC | |
| David Parrot | Chief Financial Officer | P - Open-market purchase | 1.3K | $15.00 | $20K | SEC | |
| David Parrot | Chief Financial Officer | P - Open-market purchase | 1.3K | $15.00 | $20K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Scribe Therapeutics, Inc. (SCTX). Updated in real time as new filings are submitted to the SEC.
Most-Active SCTX Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| AH Bio Fund II, L.P. | 5 | $5.00M |
| David Parrot | 5 | $40K |
| Svetlana Lucas | 4 | $45K |
| Behzad Aghazadeh | 4 | $36.26M |
| Carl L. Gordon | 4 | $15.00M |
Recent SCTX Form 8-K Material Events
- - Item 5.03, 9.01 [SEC]
Recent Insider Filings
- - AH Bio Fund II, L.P. (10% Owner)
- - Carl L. Gordon (Director)
- - ORBIMED ADVISORS LLC (Director)
- - Jennifer A. Doudna (10% Owner)
- - Behzad Aghazadeh (Director)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SCTX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
SCTX Insider Trading - FAQ
- What is the latest insider trade for SCTX?
- Scribe Therapeutics, Inc. (SCTX) had 13 insider filings in the last 90 days, with the most recent on 2026-07-29. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying SCTX stock?
- 9 insider purchases of SCTX were filed in the last 90 days, totaling $71.34M.
- How many insiders are selling SCTX stock?
- 0 insider sales of SCTX were filed in the last 90 days.
- Where can I see SCTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks SCTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $SEAH Seahawk Recycling Holdings, Inc.
- $SECZ Securitize Corp.
- $SEQC SeeQC, Inc.
- $SFHG SAMFINE CREATION HOLDINGS GROUP Ltd
- $SFPT Safepoint Holdings, Inc.
- $SGBX SAFE & GREEN HOLDINGS CORP.
- $SGN Signing Day Sports, Inc.
- $SGP SpyGlass Pharma, Inc.
- $SHAZ SharonAI Holdings Inc.
- $SHMD SCHMID Group N.V.
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live SCTX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.